How Paxlovid Works Against COVID-19
Paxlovid treats COVID-19 by stopping the SARS-CoV-2 virus from replicating inside infected cells. It combines two antiviral drugs: nirmatrelvir, which targets the virus's main protease enzyme (3CL protease or Mpro), and ritonavir, which boosts nirmatrelvir's levels by inhibiting the liver enzyme CYP3A that breaks it down.[1][2]
Nirmatrelvir binds to the active site of the 3CL protease, a protein the virus needs to cleave its polyproteins into functional parts for replication. Without this cleavage, the virus can't produce more copies of itself, reducing viral load and speeding symptom resolution.[1][3]
When and How It's Given
The FDA authorized Paxlovid for emergency use in December 2021 for high-risk adults and children over 12 within 5 days of symptom onset. Patients take three pills twice daily for 5 days: two 150 mg nirmatrelvir tablets plus one 100 mg ritonavir capsule each dose.[1][4]
Clinical trials showed it cut hospitalization and death risk by 89% in unvaccinated high-risk outpatients compared to placebo.[2][5]
Drug Interactions and Who Can't Take It
Ritonavir interacts with many drugs (over 140, including statins, blood thinners, and some heart meds) by slowing their metabolism, risking toxicity. Providers use tools like the Paxlovid interaction checker before prescribing.[1][4] It's not for those with severe kidney/liver issues or allergies to components.
Effectiveness Across Variants
Paxlovid works against original strains, Delta, and Omicron subvariants like BA.4/5 and XBB, as it targets a conserved protease site with low mutation risk. Real-world data confirm reduced hospitalizations even with newer variants.[3][6]
Common Side Effects Patients Report
Most side effects are mild: altered taste (dysgeusia, ~6%), diarrhea (~3%), hypertension, and muscle aches. Rebound COVID symptoms occur in 1-2% after treatment, but don't increase severe outcomes.[1][5]
Sources
[1]: FDA Paxlovid Fact Sheet
[2]: NEJM EPIC-HR Trial
[3]: Nature Reviews Microbiology on Mechanism
[4]: CDC Paxlovid Guidance
[5]: MMWR Rebound Analysis
[6]: IDSA Variant Update